Interpretation of the Chinese drug instructions for Pazopanib

Pazopanib (Pazopanib), trade name "Votrient", is an oral multi-target tyrosine kinase inhibitor (TKI). It works by inhibiting multiple targets such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit, etc., to inhibit tumor growth and angiogenesis, and are mainly used to treat renal cell carcinoma (RCC) and soft tissue sarcoma (STS). The following is a detailed interpretation of the Chinese package insert for pazopanib.

1. Indications and mechanism of action

Pazopanib is mainly used to treat advanced or metastatic renal cell carcinoma (RCC) and soft tissue sarcoma (STS). It is a multi-target tyrosine kinase inhibitor that can simultaneously inhibit multiple signaling pathways related to tumor growth, angiogenesis and the tumor microenvironment. Pazopanib inhibits tumor angiogenesis and reduces tumor blood supply by targeting VEGFR, PDGFR, c-Kit, etc., thereby slowing down the proliferation and spread of tumor cells. In addition, pazopanib further inhibits tumor growth by interfering with some key signals in the tumor microenvironment.

2. Usage and dosage

The usual adult dose of pazopanib is 800 mg once daily, preferably at the same time each day. This medication should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal to ensure optimal absorption of the medication. Because pazopanib may cause gastrointestinal discomfort, discomfort can be reduced by appropriately adjusting the dosage time or taking it with food. However, patients are advised to strictly follow their doctor's recommendations and dosage and not to adjust the medication on their own.

In some patients with hepatic impairment, the dose of pazopanib may need to be adjusted on a case-by-case basis. Doctors usually determine the appropriate dose based on the patient's weight, liver and kidney function, etc., and regularly evaluate the effects and side effects of the drug. Additionally, if a patient experiences serious side effects, the dose may need to be suspended or reduced.

3. Adverse reactions

Common adverse reactions of pazopanib include abnormal liver function, hypertension, diarrhea, fatigue, loss of appetite, rash, headache, nausea, etc. The severity of these side effects varies among individual patients. Common and minor side effects, such as fatigue, rash, and mild nausea, usually resolve on their own during treatment. However, some adverse reactions may be serious, such as liver damage, hypertension, and serious gastrointestinal effects.

Hepatic impairment is an important side effect of pazopanib and may lead to increased liver enzyme levels and even liver damage. Therefore, patients need to undergo regular liver function tests while taking pazopanib to detect potential liver damage as early as possible. Treatment discontinuation or dose adjustment may be necessary if jaundice or significant abnormalities in liver function occur.

High blood pressure is another common side effect, and patients need to have their blood pressure monitored regularly while taking pazopanib. If your blood pressure rises too much, you may need to control your blood pressure with medication and adjust your treatment plan according to your doctor's recommendations.

4. Contraindications and Precautions

Pazopanib should be used with caution or completely contraindicated in some special populations. The safety of pazopanib has not been fully established in pregnant and lactating women, and its use during pregnancy is not recommended. If a patient becomes pregnant or plans to become pregnant, the doctor must be informed and other treatment options considered. Pazopanib should also be avoided in nursing women because the drug may be excreted in breast milk.

In addition, pazopanib should not be used with certain drugs, especially drugs with serious drug interactions. For example, strong inhibitors of CYP3A4 (such as certain antibiotics, antifungals, etc.) may increase the blood concentration of pazopanib, thereby increasing the risk of side effects. Therefore, patients should inform their physicians about all medications they are taking before starting treatment with pazopanib to avoid adverse drug interactions.

Patients should closely monitor their health, especially blood pressure, liver function, and gastrointestinal effects while taking pazopanib. If serious side effects occur, you should contact your doctor promptly to adjust the treatment plan.

5. Long-term treatment and quality of life

Although pazopanib has significant efficacy in treating cancer, long-term use may have some impact on patients' quality of life. Common side effects, such as fatigue, rash, diarrhea, etc., may affect patients' daily life and work. Therefore, patients should pay close attention to their symptoms during treatment and maintain communication with their doctors so that any discomfort can be dealt with promptly.

In long-term treatment, doctors may adjust drug dosage or treatment regimen based on the patient's clinical response and the severity of adverse reactions. For some patients with strong responses, temporary discontinuation of the drug or switching to other drugs may be considered to improve the patient's quality of life.

In short, pazopanib, as a targeted drug, can significantly improve the survival and quality of life of some cancer patients, but it is also accompanied by certain side effects and treatment challenges. When using this drug, patients must strictly follow the doctor's instructions and undergo necessary examinations regularly to ensure the safety and effectiveness of the treatment.

References：https://www.votrient.com/